Holista Colltech (ASX:HCT) at a 52-Week Low: What’s Going On?

Sonal Goyal

21 October 2026 10:51 PM AEDT

Holista Colltech (ASX:HCT) at a 52-Week Low: What’s Going On?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

HCT touched a 52-week low on 21 October 2026 and closed at $0.039, down 11.36% for the day.
Its 31 August 2026 half-year review reported Revenue up 3.6% to $2.99 million and a net loss of $2.56 million.
The loss included about $2.66 million of one-off costs from settling the ProImmune matter for US$1.8 million.

On 21 October 2026, Holista Colltech Ltd (ASX:HCT) hit a 52-week low during the trading session. Shares closed the day at $0.039, down 11.36%. Holista Colltech is a Perth-based company that sells supplements and ingredients and is developing agricultural products.

What Holista Colltech does

Holista Colltech Limited sells nutritional supplements and ingredients through its Supplements division and is developing agriculture products such as nano urea and a poultry probiotic.

Half year review to June 2026

In an Appendix 4D announcement dated 31 August 2026 for the half year ended 30 June 2026, Holista reported group revenue of $2.99 million, up 3.6%, Gross Profit of $1.33 million and a gross Margin of 44.3% compared with 41.9%. Supplements sales rose 12.2% to $2.91 million, and agriculture sales of nano urea and poultry probiotic were $23,484.

The net loss was $2.56 million compared with $0.30 million, including about $2.66 million of one-off costs for the ProImmune matter, which was settled for US$1.8 million after an April 2026 WA Supreme Court judgment, with final payment on 10 July 2026. Excluding the item, Underlying Profit after tax was about $0.095 million.

Sector context

Healthcare and medical technology companies are assessed on clinical progress, regulatory approvals and commercial uptake, and share prices can be volatile around such events.

Risks and uncertainties

The settlement cost produced a large loss for the half, revenue is small, and agriculture sales are at an early stage. The share price is about 3.9 cents. Closing prices on a single day are not the same as the 52-week high or low price, and a 52-week extreme does not indicate where a share price will move next.

Catalysts to watch

Items to watch include supplements sales, agriculture order growth and full-year results.

Closing perspective

Holista’s half-year review described higher revenue and margin and a loss from the ProImmune settlement. Later reports will show underlying results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.